iRadimed (IRMD) Projected to Announce Earnings on Friday

iRadimed (NASDAQ:IRMD) is anticipated to issue its Q2 2026 results before the market opens on Friday, July 31st. Analysts expect iRadimed to announce earnings of $0.42 per share and revenue of $20.35 million for the quarter. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, July 31, 2026 at 11:00 AM ET.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. The business had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%.

iRadimed Stock Performance

NASDAQ IRMD opened at $94.31 on Thursday. The company has a market capitalization of $1.21 billion, a PE ratio of 51.54 and a beta of 0.90. The business’s fifty day moving average is $94.52 and its 200 day moving average is $95.76. iRadimed has a fifty-two week low of $57.58 and a fifty-two week high of $107.90.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 2,500 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the transaction, the chief executive officer directly owned 2,162,500 shares in the company, valued at approximately $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,250 shares of company stock valued at $1,836,403 in the last quarter. Corporate insiders own 34.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Quarry LP acquired a new stake in shares of iRadimed during the third quarter worth about $40,000. Tower Research Capital LLC TRC increased its holdings in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the period. Virtus Advisers LLC acquired a new position in iRadimed in the 3rd quarter worth approximately $117,000. Aquatic Capital Management LLC raised its position in iRadimed by 210,400.0% during the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock worth $150,000 after buying an additional 2,104 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new position in iRadimed during the 4th quarter worth approximately $218,000. 92.34% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IRMD has been the subject of a number of research analyst reports. Weiss Ratings lowered iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, iRadimed presently has a consensus rating of “Buy” and an average target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.